Obesity Medicine Without Insurance: How GLP-1 Era Practices Are Building Direct-Care Memberships
GLP-1 medications have made obesity medicine one of the fastest-growing niches in direct care. Here’s how to structure the membership model, monitoring schedule, and EMR workflow.
GLP-1 medications have turned obesity medicine into one of the fastest-growing niches in direct-care practice — and the reason is structural. Insurance coverage for GLP-1 drugs has been inconsistent, and as the compounded market is phased out following FDA shortage-list removals, patients are increasingly sourcing brand-name medications independently. That separates the clinical work — monitoring, titration, lab management, ongoing support — from the drug itself, and direct care prices exactly that kind of long-term relationship.
Why GLP-1 Medications Changed the Business Case for Independent Obesity Medicine
For most of the specialty’s history, obesity medicine in private practice faced a structural problem: poor insurance reimbursement for weight management visits, and a clinical value proposition that was hard to separate from whichever drug a prescriber happened to choose. GLP-1 receptor agonists changed both sides. They produce meaningful, sustained weight loss for a significant share of patients. And they are increasingly patient-sourced — patients obtain them through manufacturer programs or specialty pharmacies, not through the physician’s dispensary.
The World Health Organization issued its first global guideline on GLP-1 therapies for adults with obesity in December 2025, framing obesity as a chronic, relapsing condition requiring long-term management. That framing matters for practice design: monitoring does not end when a patient reaches goal weight. A recurring membership that prices the monitoring relationship — not a course of treatment — fits the disease model that the evidence now supports.
What a Direct-Care Obesity Medicine Membership Actually Includes
The membership covers clinical time and infrastructure, not medication. An obesity medicine membership in direct care typically includes the initial comprehensive assessment, monthly or quarterly check-in visits depending on the patient’s phase of treatment, secure messaging access between visits, lab ordering and result review in the chart, body composition monitoring, and titration decisions. Medication is a separate line item — patients source it through a manufacturer program or pharmacy of their choice.
Labs vary by practice structure. Some include wholesale lab access in the membership; others list labs as a pass-through at cost to the patient. Either way, the ordering workflow and result delivery need to be seamless: a practice managing active GLP-1 patients runs a quarterly metabolic panel as routine, and that cannot be coordinated manually at any scale.
How Do Patients Source Their GLP-1 Medications?
With compounded semaglutide and tirzepatide being phased out — the FDA removed semaglutide from the shortage list in February 2025 and tirzepatide in October 2024, and in April 2026 proposed excluding both from the 503B bulk drug substances list — the main cash-pay pathway is now manufacturer direct-to-consumer programs such as NovoCare Pharmacy (Wegovy) and LillyDirect (Zepbound). The direct-care model is well-positioned for this landscape: the practice’s value is the clinical relationship, not access to a compounded product, and the regulatory burden of 503B compounding oversight never falls on the practice.
What Is the Right Monitoring Schedule for GLP-1 Patients?
During active GLP-1 treatment, the ADA’s 2026 Standards of Care call for anthropometric measurements — weight, waist circumference, and waist-to-height ratio — every three months, alongside metabolic panels covering lipids, fasting glucose, and hepatic function. The WHO’s December 2025 global guideline reinforces this as a long-term protocol, not a short course: monitoring continues through the maintenance phase, not just through titration.
A practical monitoring rhythm for an active GLP-1 patient:
- Monthly: weight, blood pressure, reported side effects, appetite and satiety review
- Quarterly: waist circumference, waist-to-hip ratio, waist-to-height ratio, comprehensive metabolic panel, lipid panel
- Biannually: A1c for patients with prediabetes or diabetes, thyroid function if clinically indicated
- At any medication change: restart monthly check-ins until stable on the new dose or regimen
Waist-to-height ratio has emerged in the ADA 2026 and WHO 2025 guidelines as a more reliable cardiometabolic risk marker than BMI alone — it captures central adiposity independently of height and correlates better with metabolic outcomes in patients on GLP-1 therapy. A monitoring workflow that tracks waist circumference alongside weight, and computes the waist-to-height ratio automatically, gives the clinician more actionable data than the scale alone.
How to Structure Membership Tiers for an Obesity Medicine Practice
Most operating obesity medicine direct-care practices use two or three tiers based on visit frequency and patient complexity. The structure below reflects the monitoring rhythm GLP-1 treatment requires; adapt it to your patient population and workflow.
| Tier | Best for | Visit cadence | What’s included |
|---|---|---|---|
| Monitoring | Patients stable on medication with consistent weight | Quarterly visits | Check-ins, secure messaging, lab ordering and result review, body composition tracking |
| Active Management | Patients titrating or within the first six months | Monthly visits | Monthly check-ins, priority messaging, dose titration, full lab suite, body composition review |
| Complex Care | Patients with T2D, hypertension, PCOS, or other cardiometabolic comorbidities | Monthly or as-needed | Same-day access, coordinated comorbidity management, full lab suite, specialist co-management |
Federal legislation in 2026 established HSA eligibility for direct primary care membership fees — up to $150 per month for individuals and $300 per month for families. Practices that want their fees to qualify as HSA expenses typically structure their base tier at or below the individual limit. A focused obesity medicine membership may or may not meet the federal DPC statutory definition; consult a benefits attorney if HSA eligibility matters to your patients’ enrollment decision.
What Does the EMR Need to Handle for Obesity Medicine?
Standard EMR workflows were not designed for the monitoring cadence obesity medicine runs. Several capabilities matter more here than in general primary care:
- Body composition vitals that trend over time: waist circumference, hip circumference, and the derived ratios — waist-to-hip and waist-to-height — need to appear as a longitudinal trend, not as isolated data points. A physician managing a GLP-1 patient over two years needs to see direction, not hunt through individual visit records.
- Lab ordering and results in the chart: Quarterly metabolic panels are routine. Results need to arrive in the patient chart automatically, linked to the relevant visit, rather than requiring manual import.
- Note templates and snippets the practice builds: Titration visits follow a predictable structure — tolerance review, weight trend, next dose decision, plan. The practice builds its own note templates and snippets over time to match its documentation style and monitoring protocol.
- Secure messaging integrated into the clinical record: GLP-1 patients have between-visit questions — nausea management, dose timing, injection site guidance. That communication belongs in the clinical record, not a separate patient portal.
- Membership billing separate from visit codes: The practice collects a recurring membership fee, not per-visit CPT charges. The billing layer needs to handle recurring charges without insurance-claim logic wrapped around it.
- AI-assisted documentation: Titration visits are documentation-dense — current dose, weight trend, side effect inventory, lab review, plan. AI scribe capability reduces the note burden in a specialty where active patients are seen monthly.
How Obesity Medicine Practices Use SigmaMD
SigmaMD is a membership-first EMR built for direct primary care and direct-care specialty practices. For obesity medicine, the platform handles the full clinical and administrative workflow: weight and waist circumference tracking alongside hip circumference, with waist-to-hip and waist-to-height ratios computed automatically when measurements are entered; lab ordering through integrated diagnostic providers with results landing in the patient chart; note templates and snippets the practice builds to match its own titration and monitoring protocols; SigmaMD Scribe for AI-assisted visit documentation; secure patient messaging in the clinical workflow; and membership billing for recurring fees.
The vitals module tracks the cardiometabolic markers the ADA 2026 and WHO 2025 monitoring standards require. Derived ratios — waist-to-hip and waist-to-height — compute automatically from entered measurements, without a separate calculation or custom field setup. The same platform handles membership billing, the lab workflow, and clinical documentation, which matters most in a small practice running active GLP-1 patients on monthly visit cadence.
If you’re building or expanding a direct-care obesity medicine practice, book a demo with SigmaMD to see how the platform handles the monitoring rhythm, lab workflow, and membership billing in one place.
Frequently Asked Questions
Can an obesity medicine physician run a direct-care practice without offering primary care?
Yes. A focused specialty direct-care membership covering only obesity management operates on the same structural model as DPC but may have different implications for federal HSA eligibility and regulatory classification. Many obesity medicine practices that have launched recently pair with DPC primary care partners for co-management, or add a narrow primary care layer alongside obesity medicine to fit the DPC statutory definition more cleanly.
What happens to the membership when a patient pauses or stops their GLP-1?
The membership covers clinical care, not the medication. Most practices treat a medication pause as an active clinical phase — weight regain typically begins within weeks of stopping a GLP-1, and that is exactly when monitoring matters most. The visit cadence may shift to quarterly, but the membership continues. Building that expectation into the enrollment conversation reduces churn at the medication-pause point.
How do patients pay for their medications if the practice doesn’t dispense GLP-1s?
Patients source medications through manufacturer cash-pay programs or their preferred pharmacy. The practice prescribes and monitors; it does not handle the medication supply chain. This separation is also part of the compliance posture: the practice’s liability is the clinical relationship, not involvement in compounding oversight or medication distribution.
Does HSA eligibility for DPC fees apply to an obesity medicine membership?
This depends on how the membership is structured and whether it meets the federal DPC definition. The 2026 legislation uses specific statutory language that a focused specialty practice may or may not satisfy. Some practices address this by offering primary care alongside obesity management, which more clearly fits the DPC category. Consult a benefits attorney before positioning HSA eligibility as a membership benefit.
What is the right monitoring interval when a patient transitions from active titration to maintenance?
During titration, monthly visits are standard — weight trend, side effect review, next dose decision. Once a patient reaches a stable maintenance dose with stable weight, quarterly visits with messaging access in between are typically sufficient. The ADA 2026 Standards note that metabolic labs shift to every six months for stable patients, though any weight regain, change in symptoms, or new comorbidity warrants returning to monthly cadence.